* Exelixis announces positive results from phase 2 cabosun
trial of cabozantinib versus sunitinib in previously untreated
advanced renal cell carcinoma presented at esmo 2016
The post BRIEF-Exelixis announces positive results from phase 2 trial of Cabozantinib vs Sunitinib appeared first on NASDAQ.